Respiratory Virus Immunity Overview

Principles

Definition

Respiratory virus immunity is the academic field dedicated to investigating the complex interactions between the host immune system and viruses that infect the respiratory tract. It encompasses the study of innate and adaptive immune responses, immunological memory, and correlates of protection, providing foundational knowledge essential for vaccine development, therapeutic interventions, and understanding disease pathogenesis.

Ontological type

Adaptive Immunity

Vaccine Strategies

Innate Responses

Key developments

Key Figures

Antibody-Centric Immunity era

Matti Korppi [1] was active in the Antibody-Centric Immunity era (2003–2010), with affiliations to Imperial College London [3] and the University of Eastern Finland [4]. His key contribution, highlighted by the Rhinovirus-induced wheezing in infancy paper [7], linked early-life viral wheeze to increased asthma risk, underscoring why humoral-based protection and prophylaxis dominated this era. Matti Waris [2] is associated with the University of Turku [5] and Tampere University [6] during this era. As a co-author of the Rhinovirus-induced wheezing in infancy paper [7], Waris helped advance understanding of the rhinovirus role in infancy and its implications for antibody-centric immunity and early prophylaxis.

Prefusion F Immunogen Era era

José A. Melero [1] is a prominent RSV immunology researcher whose work in this era intersects institutions such as The University of Texas Health Science Center at San Antonio [3] and University of Geneva [4]. His key contributions in this era include characterizing neutralizing antibodies that target the preactive form of the RSV F glycoprotein, as described in Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention [7], and in Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein [8], which underscored why stabilizing the prefusion F is crucial for broad, potent neutralization and for guiding immunogen design. David S.C. Hui [2] is affiliated with Boston University [5] and Chinese University of Hong Kong [6] during this period. His contribution in this era centers on documenting the clinical burden of RSV disease in adults hospitalized for RSV infections, as described in High Morbidity and Mortality in Adults Hospitalized for Respiratory Syncytial Virus Infections [9], highlighting the public health relevance that informs prefusion F vaccine strategies and safety considerations.

Population Immunity Modulation era

H. Keipp Talbot [1] is affiliated with Johns Hopkins University [3] and University of Washington [4] during this era. Her key contributions include the Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023 [7], which provided critical guidance for vaccination strategies and population immunity during this era. Adam Meijer [2] is affiliated with University of Maryland, College Park [5] and University of York [6] during this era. His work includes the Low levels of respiratory syncytial virus activity in Europe during the 2020/21 season: what can we expect in the coming summer and autumn/winter [8], findings that helped inform surveillance, exposure histories, and immunity projections during the population immunity modulation era.